 Novo Nordisk AS NYSE: NVO has agreed to acquire Dicerna Pharmaceuticals Inc NASDAQ: DRNA for 38.25 per share in cash, representing a total equity value of 3.3 billion and a premium of 80 to Dicernas closing price on November 17, 2021. The acquisition of Dicerna accelerates Novo Nordisks research within RNAi and expands the usage of the RNAi technology, said Marcus Schindler, the CSO of Novo Nordisk. 